SAA acts with a mechanism of positive feedback on leukemia cells by increasing the expression of indoleamine 2,3-dioxygenase-1 (IDO1), the rate-limiting enzyme for Kyn synthesis, thereby enabling AML progression. This evidence concerns the gene IDO1 and acute myeloid leukemia.